Jiangsu Nhwa Pharmaceutical Co., Ltd.
002262.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$21.95B
Close$
$27.59
27.3% upside
Current Fair Value
27.3% upsideUndervalued by 27.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $21.95 Billion |
|---|---|
| Enterprise Value | $21.18 Billion |
| Dividend Yield | $0.40 (1.85%) |
| Earnings per Share | $1.05 |
| Beta | -0.2 |
| Outstanding Shares | 1,009,852,543 |
Return
| Return on Equity | 13.08% |
|---|---|
| Return on Assets | 11.49% |
| Return on Invested Capital | 14.28% |
Valuation & Multiples
| P/E Ratio | 20.04 |
|---|---|
| PEG | 341.13 |
| Price to Sales | 3.61 |
| Price to Book Ratio | 2.71 |
| Enterprise Value to Revenue | 3.46 |
| Enterprise Value to EBIT | 17.52 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
October 24, 2026
EPS Estimate
$0.45
Average shareholder expectationRevenue Estimate
$1.58 B
Average shareholder expectationNext Earnings Call
Expected Date
March 25, 2027
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$1.55 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Jiangsu Nhwa Pharmaceutical Co., Ltd.
6,003 employees
CEO: Jiaquan Sun Jiangsu Nhwa Pharmaceutical Co., LTD operates as a global pharmaceutical entity, focusing on the research, production, and sale of treatments for the central nervous system, along with cardiovascular and cerebrovascular ailments. Its com...